Hambro Perks Acquisition, the first blank-check firm to list in London after a rule change, is discussing a possible merger with closely held pharmaceutical company Istesso Ltd., Bloomberg writes, citing reporting from Sky News. Sources were not identified.
The SPAC is in advanced talks on a deal that may value the UK developer of drugs for chronic diseases at several hundred million pounds, according to the report.
Hambro Perks raised 140 million pounds (about $187 million) in a November 2021 IPO. Read more.
Source: Hambro Perks SPAC Reportedly Eyes Merger With Biotech Istesso